Bio-Amd Inc (BIAD) 0.0460 $BIAD
Bio-AMD, Inc. Restructuring, MIDS Project Commences
Marketwired - Tue Jun 21, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - Jun 21, 2016) - Bio-AMD, Inc. and Bio-AMD UK Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) here provides an update on our MIDS project and a restructuring of our medical device subsidiary operations.
Bio-AMD, Inc.; COAG PT/INR Point of Care Hemostasis Project & Patent Update
Marketwire Canada - Thu May 12, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - May 12, 2016) - Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) here provides an update on its PT/INR COAG project and on other matters around its business.
Bio-AMD, Inc.: First MIDS Patent Grant Likely, Shareholder Update
ACCESSWIRE - Mon Jan 11, 7:30AM CST
DARESBURY, ENGLAND / ACCESSWIRE / January 11, 2016 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to provide an update on progress for shareholders.
Bio-AMD, Inc.; United States Patent Granted for PT/INR Technology
ACCESSWIRE - Thu Jul 16, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / July 16, 2015 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" (OTCQB: BIAD), is pleased to announce that it has recently received formal notice of a grant of a United States Patent ("Grant" for its Low Volume Assay Apparatus used in its point of care system for the measurement of Prothrombin Time / International Normalized Ratio ("PT/INR".
Bio-AMD, Inc.; Ethics Approval for Patient Testing Study
ACCESSWIRE - Thu Jul 02, 7:45AM CDT
LONDON, ENGLAND, UK /ACCESSWIRE / July 2, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD), is pleased to announce it has obtained a "favourable ethical opinion" from the North West Centre of Research Ethics Committees of the UK's National Research Ethics Service (together, "NRES", enabling it to undertake sample testing from patients as part of its development program.
Bio-AMD, Inc.; MIDS Proof of Market Report
ACCESSWIRE - Mon Jun 01, 7:37AM CDT
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" (OTCQB: BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report", part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS" technology.
Bio-AMD, Inc.; Implementation of ISO9001 and ISO 13485 Quality Standards
ACCESSWIRE - Thu May 21, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / May 21, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to announce that it is to formalise implementation of the International Organisation for Standardization quality standards ISO 9001:2008 and ISO 13485:2012.
Bio-AMD, Inc.; Grant Funded Technical Support from the University of Liverpool
ACCESSWIRE - Tue May 05, 7:45AM CDT
LONDON, ENGLAND /ACCESSWIRE / May 5, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" (OTCQB: BIAD), is pleased to announce that it has recently received grant funded assistance from the University of Liverpool to assist in the further development of its micro-fluidic technology, especially in relation to our proposed Magnetic Immunoassay Detection System ("MIDS" program.
Bio-AMD, Inc.; General Update and MIDS Plans
eTeligis - Tue Apr 14, 12:11AM CDT
LONDON, ENGLAND, United States, via ETELIGIS INC., 03/31/2015 - - Bio-AMD, Inc. (OTCQB: BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015.
Bio-AMD, Inc.; General Update & MIDS Plans
ACCESSWIRE - Tue Mar 31, 7:31AM CDT
LONDON, ENGLAND / ACCESSWIRE / March 31, 2015 / Bio-AMD, Inc. (OTCQB:BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015.
Bio-AMD, Inc. Agreement with Sysmex & General Update
ACCESSWIRE - Tue Jan 27, 7:46AM CST
LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) provides an update on the Company's plans for 2015.
Bio-AMD, Inc., Innovate UK Offer of Funding Assistance
ACCESSWIRE - Wed Nov 19, 8:16AM CST
LONDON, ENGLAND / ACCESSWIRE / November 19, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) is pleased to announce that it has received an offer of a funding award assistance from Innovate UK, the UK's innovation agency, for a Proof of Market report covering the Company's Magnetic Immunoassay Detection System ("MIDS".
Bio-AMD, Inc. Restructuring, MIDS Project Commences
Marketwired - Tue Jun 21, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - Jun 21, 2016) - Bio-AMD, Inc. and Bio-AMD UK Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) here provides an update on our MIDS project and a restructuring of our medical device subsidiary operations. Bio-AMD, Inc.; COAG PT/INR Point of Care Hemostasis Project & Patent Update
Marketwire Canada - Thu May 12, 7:01AM CDT
DARESBURY, UNITED KINGDOM--(Marketwired - May 12, 2016) - Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) here provides an update on its PT/INR COAG project and on other matters around its business. Bio-AMD, Inc.: First MIDS Patent Grant Likely, Shareholder Update
ACCESSWIRE - Mon Jan 11, 7:30AM CST
DARESBURY, ENGLAND / ACCESSWIRE / January 11, 2016 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to provide an update on progress for shareholders.
Bio-AMD, Inc.; United States Patent Granted for PT/INR Technology
ACCESSWIRE - Thu Jul 16, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / July 16, 2015 / Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
(OTCQB: BIAD), is pleased to announce that it has recently received formal notice of a grant of a United States Patent ("Grant" for its Low Volume Assay Apparatus used in its point of care system for the measurement of Prothrombin Time / International Normalized Ratio ("PT/INR". Bio-AMD, Inc.; Ethics Approval for Patient Testing Study
ACCESSWIRE - Thu Jul 02, 7:45AM CDT
LONDON, ENGLAND, UK /ACCESSWIRE / July 2, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD), is pleased to announce it has obtained a "favourable ethical opinion" from the North West Centre of Research Ethics Committees of the UK's National Research Ethics Service (together, "NRES", enabling it to undertake sample testing from patients as part of its development program. Bio-AMD, Inc.; MIDS Proof of Market Report
ACCESSWIRE - Mon Jun 01, 7:37AM CDT
FLONDON, ENGLAND / ACCESSWIRE / June 1, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
(OTCQB: BIAD), is pleased to announce that it has recently received an independent Proof of Market report ("Report", part-funded by a UK government grant, on its novel Magnetic Immunoassay Detection System ("MIDS" technology. Bio-AMD, Inc.; Implementation of ISO9001 and ISO 13485 Quality Standards
ACCESSWIRE - Thu May 21, 7:45AM CDT
LONDON, ENGLAND / ACCESSWIRE / May 21, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company" OTCQB: BIAD) is pleased to announce that it is to formalise implementation of the International Organisation for Standardization quality standards ISO 9001:2008 and ISO 13485:2012.
Bio-AMD, Inc.; Grant Funded Technical Support from the University of Liverpool
ACCESSWIRE - Tue May 05, 7:45AM CDT
LONDON, ENGLAND /ACCESSWIRE / May 5, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
(OTCQB: BIAD), is pleased to announce that it has recently received grant funded assistance from the University of Liverpool to assist in the further development of its micro-fluidic technology, especially in relation to our proposed Magnetic Immunoassay Detection System ("MIDS" program. Bio-AMD, Inc.; General Update and MIDS Plans
eTeligis - Tue Apr 14, 12:11AM CDT
LONDON, ENGLAND, United States, via ETELIGIS INC., 03/31/2015 - - Bio-AMD, Inc. (OTCQB: BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015. Bio-AMD, Inc.; General Update & MIDS Plans
ACCESSWIRE - Tue Mar 31, 7:31AM CDT
LONDON, ENGLAND / ACCESSWIRE / March 31, 2015 / Bio-AMD, Inc. (OTCQB:BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015. Bio-AMD, Inc. Agreement with Sysmex & General Update
ACCESSWIRE - Tue Jan 27, 7:46AM CST
LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) provides an update on the Company's plans for 2015. Bio-AMD, Inc., Innovate UK Offer of Funding Assistance
ACCESSWIRE - Wed Nov 19, 8:16AM CST
LONDON, ENGLAND / ACCESSWIRE / November 19, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) is pleased to announce that it has received an offer of a funding award assistance from Innovate UK, the UK's innovation agency, for a Proof of Market report covering the Company's Magnetic Immunoassay Detection System ("MIDS". 
